MXC: $0.044

An EU pharmaceutical licensed company, MGC Pharmaceuticals Ltd (ASX: MXC),(MGCLF: OTC US)  is driven by the goal to be a global innovator in Phytocannabinoid-based medicine within the biopharmaceutical industry. With many years of real-world, technical and professional experience, MGC Pharma’s founders are all celebrated trailblazers in the Phytocannabinoid industry. MGC Pharma’s main objective is to create and supply superb Cannabinoid based pharmaceutical products for medical markets in North America, Europe, and Australasia.

Read More Read Edison Research On MGC

Endlessly producing value for investors with high yield cultivation, tactical joint ventures, and over 40 years’ collective experience, MGC Pharmaceuticals is a leader in the Medical Cannabis industry. MGC Pharma operates under high standards of QA and QC to diverse sections of the Medical Cannabis industry, permitting us to meet and surpass Good Manufacturing Practice (GMP) and GACP protocols, all over the world.

Read More

Understanding that we work in an evolving industry which resonates worldwide, MGC Pharmaceuticals places high importance on global activities and supply chain. Unified supply and ability to function dynamically are essential. It permits our IP and experience to enable entry into new markets, helps with the growth of innovation investigation and research institutions (from the government to commercial to educational) and guarantees our products will seamlessly and reliably reach patients and customers, with the strictest QC and QA.

Read More

We’re devoted to providing you with the latest company information. This comprises of ASX announcements, financial reports, and other significant updates. You can also access FAQs and see the latest share price information here. MGC Pharmaceuticals trades on the Australian Securities Exchange (ASX) under the ticker code MXC.

Read More
Why Phytocannabinoid-based medicines

Download our publications on Medicinal Cannabis in Australia, Science, Regulation and the industry as a whole. Developed in partnership with prestigious universities, academia and pioneers in the industry, our publications set out the key challenges, risks and opportunities associated with establishing a national Medicinal Cannabis scheme in Australia.

Latest MGC Annual Report
Investor Information

Sign up to MGC Pharma’s Investor Information to receive the latest news, updates, announcements and investor presentations, straight to your inbox.

MGC Pharmaceuticals partners and collaborates with academia, worldwide prominent universities and companies all over the world to conduct extensive research and develop the highest quality products for our patients.

Research and Educational Partners

Distribution Partners